Ozempic

Active Ingredient(s): Semaglutide
FDA Approved: * December 5, 2017
Pharm Company: * NOVO NORDISK INC
Category: Diabetes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Ozempic Overview

Semaglutide (USAN; trade name Ozempic) is a pharmaceutical drug developed by Danish company Novo Nordisk. Originally developed for the treatment of type 2 diabetes in 2012,[1][2] it was found in 2017 that it can be used for the treatment of obesity.[3] The drug has been approved by the US Food and Drug Administration (FDA) in 2017, and by the European Commission, the Health Canada and the Japanese Ministry of Health, Labour and Welfare in 2018. ...

Read more Ozempic Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Semaglutide

Recent Ozempic Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Semaglutide

Solution: 2mg/1.5ml (1.34mg/ml)

Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Ozempic: (2 results)

Sorted by National Drug Code

0169-4132 Ozempic 1.34 mg/ml Subcutaneous Injection, Solution by Novo Nordisk
0169-4136 Ozempic 1.34 mg/ml Subcutaneous Injection, Solution by Novo Nordisk

Other drugs which contain Semaglutide or a similar ingredient: (1 result)

SEMAGLUTIDE